Abstract
Evidence continues to accumulate that cyclooxygenase-2 (COX-2), an inducible COX isoform, represents a potential pharmacological target for the prevention and treatment of cancer, including tumors affecting the entire upper aerodigestive tract. Studies in experimental models of these malignancies show that selective COX-1 inhibitors reduce tumor formation and growth. Clinical studies have been initiated to determine the chemoprotective effects of selective COX-2 inhibitors in patients with oral leukoplakia and Barrett's esophagus, and other studies are assessing the feasibility of incorporating these agents into existing treatment modalities for patients with locally advanced or metastatic cancer.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / metabolism
-
Adenocarcinoma / prevention & control
-
Angiogenesis Inhibitors / therapeutic use*
-
Animals
-
Anticarcinogenic Agents / therapeutic use*
-
Barrett Esophagus / drug therapy*
-
Barrett Esophagus / metabolism
-
Barrett Esophagus / prevention & control
-
Carcinoma, Squamous Cell / drug therapy
-
Carcinoma, Squamous Cell / metabolism
-
Carcinoma, Squamous Cell / prevention & control
-
Cyclooxygenase 2
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors / therapeutic use*
-
Head and Neck Neoplasms / drug therapy*
-
Head and Neck Neoplasms / metabolism
-
Head and Neck Neoplasms / prevention & control
-
Humans
-
Isoenzymes / metabolism
-
Membrane Proteins
-
Neovascularization, Pathologic / enzymology
-
Prostaglandin-Endoperoxide Synthases / metabolism
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / metabolism
-
Stomach Neoplasms / prevention & control
Substances
-
Angiogenesis Inhibitors
-
Anticarcinogenic Agents
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors
-
Isoenzymes
-
Membrane Proteins
-
Cyclooxygenase 2
-
PTGS2 protein, human
-
Prostaglandin-Endoperoxide Synthases